Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/53538
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcGregor, C.en
dc.contributor.authorSrisurapanont, M.en
dc.contributor.authorMitchell, A.en
dc.contributor.authorWickes, W.en
dc.contributor.authorWhite, J.en
dc.date.issued2008en
dc.identifier.citationJournal of Substance Abuse Treatment, 2008; 35(3):334-342en
dc.identifier.issn0740-5472en
dc.identifier.issn1873-6483en
dc.identifier.urihttp://hdl.handle.net/2440/53538-
dc.descriptionCopyright © 2008 Elsevier Inc. All rights reserved.en
dc.description.abstractThe safety and tolerability of modafinil (400 mg/day, n = 14) and mirtazapine (60 mg/day, n = 13) in inpatient methamphetamine withdrawal treatment were compared to a historical comparison group receiving treatment as usual (pericyazine, 2.5-10 mg/day, n = 22). Modafinil and mirtazapine were well tolerated, producing minimal positive subjective effects and no discontinuation effects in this open-label study. Side effects were mild and transient. Aches and pains were most commonly reported by participants receiving mirtazapine, whereas headache was reported by modafinil-treated participants. Modafinil-treated participants had a milder withdrawal syndrome as measured by the Amphetamine Cessation Symptom Assessment and less sleep disturbance in comparison to mirtazapine. Pericyazine was associated with a more severe withdrawal syndrome in comparison to mirtazapine and modafinil. Both modafinil and mirtazapine were safe and well tolerated in methamphetamine withdrawal treatment. However, these early findings of efficacy in symptom amelioration should be replicated in an adequately powered, randomized, placebo-controlled double-blind design.en
dc.description.statementofresponsibilityCatherine McGregor, Manit Srisurapanont, Amanda Mitchell, Wendy Wickes and Jason M. Whiteen
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/525475/description#descriptionen
dc.language.isoenen
dc.publisherPergamon-Elsevier Science Ltden
dc.subjectHumans; Sleep Disorders; Amphetamine-Related Disorders; Substance Withdrawal Syndrome; Benzhydryl Compounds; Mianserin; Phenothiazines; Central Nervous System Stimulants; Antidepressive Agents, Tricyclic; Severity of Illness Index; Adult; Middle Aged; Inpatients; Substance Abuse Treatment Centers; Female; Maleen
dc.titleSymptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usualen
dc.typeJournal articleen
dc.identifier.rmid0020082923en
dc.identifier.doi10.1016/j.jsat.2007.12.003en
dc.identifier.pubid41804-
pubs.library.collectionPharmacology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Pharmacology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.